Most common adverse events related to study treatment that occurred in 5% or more of patients in either treatment group during period 1
| . | Plerixafor (n = 147) . | Placebo (n = 151) . |
|---|---|---|
| Any related adverse events, n (%) | 95 (64.6) | 67 (44.4) |
| Gastrointestinal disorders | ||
| Diarrhea | 27 (18.4) | 8 (5.3) |
| Nausea | 24 (16.3) | 11 (7.3) |
| Vomiting | 8 (5.4) | 4 (2.7) |
| General disorders and administration site conditions | ||
| Fatigue | 12 (8.2) | 5 (3.3) |
| Injection site erythema | 30 (20.4) | 5 (3.3) |
| Musculoskeletal and connective tissue disorders | ||
| Bone pain | 14 (9.5) | 12 (7.9) |
| Nervous system disorders | ||
| Headache | 8 (5.4) | 13 (8.6) |
| Paresthesia | 11 (7.5) | 11 (7.3) |
| . | Plerixafor (n = 147) . | Placebo (n = 151) . |
|---|---|---|
| Any related adverse events, n (%) | 95 (64.6) | 67 (44.4) |
| Gastrointestinal disorders | ||
| Diarrhea | 27 (18.4) | 8 (5.3) |
| Nausea | 24 (16.3) | 11 (7.3) |
| Vomiting | 8 (5.4) | 4 (2.7) |
| General disorders and administration site conditions | ||
| Fatigue | 12 (8.2) | 5 (3.3) |
| Injection site erythema | 30 (20.4) | 5 (3.3) |
| Musculoskeletal and connective tissue disorders | ||
| Bone pain | 14 (9.5) | 12 (7.9) |
| Nervous system disorders | ||
| Headache | 8 (5.4) | 13 (8.6) |
| Paresthesia | 11 (7.5) | 11 (7.3) |